Sees FY24 revenue $2.45B-$2.48B, consensus $2.47B. “We are pleased with our strong finish in Q4 and our overall full year performance,” commented Keith Pfeil, CFO. “Excluding the impacts of the September 1, 2023 merger with NuVasive, Inc., legacy Globus fourth quarter revenue was approximately $302.9 million, an increase of 10.4 percent over the prior year fourth quarter. Full year 2023 legacy Globus revenue was approximately $1.152 billion or 12.7 percent higher over the prior year. Looking ahead, we are well positioned to execute on our objectives for 2024 as we remain focused on the priorities of sales growth, continued merger integration activities and realizing synergy capture.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMED:
- Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
- Globus Medical price target lowered to $83 from $86 at Barclays
- Globus Medical price target raised to $58 from $53 at Truist
- Globus Medical price target raised to $71 from $67 at Canaccord
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
